375355-32-1

Usage

Synthetic substance

Commonly used in research and medicinal applications 1-benzoylpiperidine-4-carboxamide is a man-made compound that is widely utilized in scientific studies and for creating medications.

Class

Piperidine carboxamides 1-benzoylpiperidine-4-carboxamide belongs to a specific group of chemical compounds known as piperidine carboxamides, which share a similar structure and properties.

Intermediate in synthesis

Used in the synthesis of various pharmaceuticals and organic compounds 1-benzoylpiperidine-4-carboxamide often serves as a starting material or building block in the creation of other medications and organic molecules.

Potential as a psychoactive agent

Known for its ability to affect the mind and mental processes This chemical has properties that may influence an individual's mental state, making it a subject of interest for researchers studying psychoactive substances.

Neuroprotective properties

May help protect nerve cells from damage 1-benzoylpiperidine-4-carboxamide has shown promise in safeguarding neurons from various types of harm, which could be beneficial in treating neurological disorders.

Potential medical applications

Studied for its possible uses in treating various health conditions While the specific applications are still being researched, 1-benzoylpiperidine-4-carboxamide has demonstrated potential in addressing a range of medical issues.

Therapeutic effects

Of interest for its potential healing and health benefits Researchers are investigating the possible positive impact 1-benzoylpiperidine-4-carboxamide could have on human health and wellbeing.

Need for further research

Pharmacological properties and potential uses not yet fully understood Although 1-benzoylpiperidine-4-carboxamide has shown promise, more studies are needed to fully comprehend its properties and possible applications in medicine and other fields.

Upstream product

• 39546-32-2 4-carboxamidopiperidine 
• 98-88-4 benzoyl chloride 
• 5274-99-7 1-benzoylisonipecotic acid 
• 136081-74-8 ethyl 1-benzoyl-4-piperidine-carboxylate 
• 1126-09-6 4-carbethoxypiperidine 

Downstream Products

• 173340-23-3 tert-butyl ((1-benzylpiperidin-4-yl)methyl)carbamate 
• 135632-53-0 tert-butyl N-(4-piperidinylmethyl)carbamate 
• 757236-90-1 2-amino-N-(1-benzyl-piperidin-4-ylmethyl)-acetamide 
• 88915-26-8 4-aminomethyl-1-benzylpiperidine 

Relevant academic research and scientific papers

The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity

The enzymatic activity of butyrylcholinesterase (BChE) in the brain increases with the progression of Alzheimer's disease, thus classifying BChE as a promising drug target in advanced Alzheimer's disease. We used structure-based drug discovery approaches to develop potent, selective, and reversible human BChE inhibitors. The most potent, compound 3, had a picomolar inhibition constant versus BChE due to strong cation-π interactions, as revealed by the solved crystal structure of its complex with human BChE. Additionally, compound 3 inhibits BChE ex vivo and is noncytotoxic. In vitro pharmacokinetic experiments show that compound 3 is highly protein bound, highly permeable, and metabolically stable. Finally, compound 3 crosses the blood-brain barrier, and it improves memory, cognitive functions, and learning abilities of mice in a scopolamine model of dementia. Compound 3 is thus a promising advanced lead compound for the development of drugs for alleviating symptoms of cholinergic hypofunction in patients with advanced Alzheimer's disease.

N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: Potential multifunctional anti-Alzheimer's agents

In the brains of patients with Alzheimer's disease, the enzymatic activities of butyrylcholinesterase (BChE) and monoamine oxidase B (MAO-B) are increased. While BChE is a viable therapeutic target for alleviation of symptoms caused by cholinergic hypofunction, MAO-B is a potential therapeutic target for prevention of neurodegeneration in Alzheimer's disease. Starting with piperidine-based selective human (h)BChE inhibitors and propargylamine-based MAO inhibitors, we have designed, synthesized and biochemically evaluated a series of N-propargylpiperidines. All of these compounds inhibited hBChE with good selectivity over the related enzyme, acetylcholinesterase, and crossed the blood-brain barrier in a parallel artificial membrane permeation assay. The crystal structure of one of the inhibitors (compound 3) in complex with hBChE revealed its binding mode. Three compounds (4, 5, 6) showed concomitant inhibition of MAO-B. Additionally, the most potent hBChE inhibitor 7 and dual BChE and MAO-B inhibitor 6 were non-cytotoxic and protected neuronal SH-SY5Y cells from toxic amyloid β-peptide species.

Straightforward synthesis of orthogonally protected piperidin-3- ylmethanamine and piperidin-4-ylmethanamine derivatives

The 1,3- and 1,4-disubstituted piperidines are important building blocks in medicinal chemistry and drug discovery. We present the synthesis of orthogonally protected piperidin-3-ylmethanamine and piperidin-4-ylmethanamine derivatives from commercially available nipecotamide, isonipecotamide, nipecotic acid and isonipecotic acid. This is a straightforward two-step procedure that gives high overall yields. Purification of the intermediates using this procedure is not necessary, and the final compounds are purified by simple flash column chromatography.

Synthesis and evaluation of tacrine-E2020 hybrids as acetylcholinesterase inhibitors for the treatment of Alzheimer's disease

Tacrine-E2020 hybrids and some related compounds were prepared and their bioactivities on the Alzheimer's Disease were assayed. The optimum hybrid inhibitor 3 is much more potent and selective than tacrine in vitro. Tacrine-E2020 hybrids and some related compounds were prepared and their bioactivities on the Alzheimer's disease were assayed. The optimum hybrid inhibitor 3 is 37-fold more potent and 31-fold more selective than tacrine in vitro.